Get started
Author

Irene Seipelt

Current View on the Mechanism of Action of Perifosine in Cancer
2014 · Joachim Fensterle, Babette Aicher, et al. · Anti-Cancer Agents in Medicinal Chemistry · 35
A Convenient Synthesis of Novel 2,8-Disubstituted Pyrido[3,4-b]pyrazines Possessing Biological Activity
2011 · Pascal Marchand, Maud Antoine, et al. · Synthesis · 22
Discovery of 7‐Aryl‐Substituted (1,5‐Naphthyridin‐4‐yl)ureas as Aurora Kinase Inhibitors
2013 · Julien Defaux, Maud Antoine, et al. · ChemMedChem · 12
Discovery of (7-aryl-1,5-naphthyridin-2-yl)ureas as dual inhibitors of ERK2 and Aurora B kinases with antiproliferative activity against cancer cells
2014 · Julien Defaux, Maud Antoine, et al. · Bioorganic & Medicinal Chemistry Letters · 9
Efficient synthesis of novel disubstituted pyrido[3,4-b]pyrazines for the design of protein kinase inhibitors
2015 · Maud Antoine, Tilmann Schuster, et al. · MedChemComm · 5
New generation of anilino-substituted pyridopyrazine-urea derivatives show highly selective PI3K-inhibition
2007 · Irene Seipelt, Eckhard Claus, et al. · Cancer Research · 5
Abstract 871: Dual inhibition of PI3K and Erk1/2 shows synergy and efficacy in human tumor cells, either by using drug combinations or novel dual PI3K/Erk inhibitors
2012 · Irene Seipelt, Matthias Gerlach, et al. · Cancer Research · 3
Overexpression, Purification, and Use of a Soluble Human Interleukin-4 Receptor α-chain/Igγ1 Fusion Protein for Ligand Binding Studies
1997 · Irene Seipelt, Silke H. Hoffmann, et al. · Biochemical and Biophysical Research Communications · 3
ChemInform Abstract: A Convenient Synthesis of Novel 2,8‐Disubstituted Pyrido[3,4‐b]pyrazines Possessing Biological Activity.
2012 · Maud Antoine, Matthias Gerlach, et al. · ChemInform · 1
Abstract 3563: A highly selective Erk1/2 Inhibitor with in-vivo anti tumor potency
2011 · Irene Seipelt, Eckhard Guenther, et al. · Cancer Research · 1
Isolation and refolding of a mutant methionine‐free interleukin‐2‐receptor α chain synthesized as a fusion protein in Escherichia coli
1994 · Irene SEIPELT, Joachim W. ENGELS · European Journal of Biochemistry · 1
PDF
Abstract 3711: Erk inhibition as a therapeutic option for the treatment of Raf- and Mek- inhibitor resistant tumors
2014 · Irene Seipelt, Peter Schmidt, et al. · Cancer Research
AEZS-131- ein hochselektiver ERK-Inhibitor: Charakterisierung und präklinische Testung im tripelnegativen Mammakarzinom (TNBC)
2012 · JB Engel, I Seipelt, et al. · Geburtshilfe und Frauenheilkunde
AEZS-131 - ein hochselektiver ERK-Inhibitor: Charakterisierung und präklinische Testung im tripelnegativen Mammakarzinom (TNBC)
2012 · J Engel, I Seipelt, et al. · Senologie - Zeitschrift für Mammadiagnostik und -therapie
P3-18-06: AEZS-131 – A Highly Selective ERK-Inhibitor: Characterization and Preclinical Testing in Triple Negative Breast Cancer (TNBC).
2011 · JB Engel, I Seipelt, et al. · Cancer Research
197 AEZS-132, a new orally bioavailable PI3K/Erk inhibitor with antitumor effects
2010 · I. Seipelt, M. Gerlach, et al. · European Journal of Cancer Supplements
98 AEZS-129, an orally active PI3K inhibitor in preclinical development
2010 · I. Seipelt, E. Guenther, et al. · European Journal of Cancer Supplements
Abstract 4474: Dual inhibitors for PI3K and Erk induce growth inhibition of tumor cells
2010 · Irene Seipelt, Matthias Gerlach, et al. · Cancer Research
Abstract 3856: A highly selective Erk-inhibitor with antiproliferative efficacy and the potential for combination therapy with modulators of the PI3K pathway
2010 · Irene Seipelt, Lars Blumenstein, et al. · Cancer Research
Works count: 19
Citation count: 97
H-index: 5
I10-index: 3
Year
Topic
Type